Evidence map›Paper›PMID 33481052›Full record

ArticleCalcified tissue international2021

Secreted Phosphoprotein 24 is a Biomarker of Mineral Metabolism.

Mandy E Turner, Christine A White, Sarah M Taylor, Kathryn Neville, Karen Rees-Milton, Wilma M Hopman, Michael A Adams, Tassos Anastassiades, Rachel M Holden

Abstract read
PubMed Publisher
In one paragraph

Article in Calcified tissue international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mandy E TurnerDepartment of Biomedical and Molecular Sciences, Queen's University, 3048C Etherington Hall, Kingston, ON, K7L 3V6, Canada.ORCID 0000-0001-6431-5077
Christine A WhiteDepartment of Medicine, Queen's University, Kingston, ON, K7L 3V6, Canada.
Sarah M TaylorDepartment of Biomedical and Molecular Sciences, Queen's University, 3048C Etherington Hall, Kingston, ON, K7L 3V6, Canada.
Kathryn NevilleDepartment of Biomedical and Molecular Sciences, Queen's University, 3048C Etherington Hall, Kingston, ON, K7L 3V6, Canada.
Karen Rees-MiltonDepartment of Medicine, Queen's University, Kingston, ON, K7L 3V6, Canada.
Wilma M HopmanKGH Research Institute, Kingston Health Sciences Centre, Kingston, ON, K7L 3V6, Canada.
Michael A AdamsDepartment of Biomedical and Molecular Sciences, Queen's University, 3048C Etherington Hall, Kingston, ON, K7L 3V6, Canada.
Tassos AnastassiadesDepartment of Biomedical and Molecular Sciences, Queen's University, 3048C Etherington Hall, Kingston, ON, K7L 3V6, Canada.
Rachel M HoldenDepartment of Biomedical and Molecular Sciences, Queen's University, 3048C Etherington Hall, Kingston, ON, K7L 3V6, Canada. Rachel.Holden@kingstonhsc.ca.
Queen's University · CA

Funding

CIHR 201003MOP
6 · The paper itself

Abstract

The 24 kD form of secreted phosphoprotein (SPP-24), a cytokine-binding bone matrix protein with various truncated C-terminal products, is primarily synthesized by the liver. SPP-24 shares homology with fetuin-A, a potent vascular and soft tissue calcification inhibitor and SPP-24 is one component of calciprotein particles (CPPs), a circulating fetuin-mineral complex. The limited molecular evidence to date suggests that SPP-24 may also function as an inhibitor of bone formation and ectopic vascular calcification, potentially through bone morphogenic protein 2 (BMP-2) and Wnt-signaling mediated actions. The C-terminal products of SPP-24 bind to BMP-2 and attenuate BMP-2-induced bone formation. The aim of this study was to assess circulating SPP-24 in relation to kidney function and in concert with markers of mineral metabolism in humans. SPP-24 was measured in the serum of total of 192 subjects using ELISA-based measurements. Subjects were participants of one of two cohorts: (1) mGFR Cohort (n = 80) was participants of a study of measured GFR (mGFR) using inulin urinary clearance, recruited mostly from a chronic kidney disease clinic with low-range kidney function (eGFR 38.7 ± 25.0 mL/min/1.73 m

Indexed as

MineralsAgedBiomarkersCanadaFemaleGlomerular Filtration RateHumansKidneyMaleMiddle AgedPhosphoproteinsRenal Insufficiency, ChronicBiomarkersMineralsPhosphoproteinsSPP2 protein, humanBiomarkerMineral metabolismSecreted phosphoprotein 24

Identifiers

PMID33481052
OpenAlexW3124491368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.